"10.1371_journal.pone.0061120","plos one","2013-05-08T00:00:00Z","Kenneth B Lewis; Richard J Hughes; Melinda S Epstein; Neil C Josephson; Christine L Kempton; Craig M Kessler; Nigel S Key; Tom E Howard; Rebecca Kruse-Jarres; Jeanne M Lusher; Christopher E Walsh; Raymond G Watts; Ruth A Ettinger; Kathleen P Pratt; the PATH ( P ersonalized A lternative T herapies for H aemophilia) Study Investigators","Puget Sound Blood Center Research Institute, Seattle, Washington, United States of America; Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States of America; Division of Hematology, University of Washington, Seattle, Washington, United States of America; Emory University, Atlanta, Georgia, United States of America; Georgetown University, Washington, DC, United States of America; University of North Carolina, Chapel Hill, North Carolina, United States of America; Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at UCLA and Department of Pathology and Laboratory Medicine, Keck School of Medicine at USC, Los Angeles, California, United States of America; Tulane University, New Orleans, Louisiana, United States of America; Wayne State University, Detroit, Michigan, United States of America; Mount Sinai School of Medicine, New York, New York, United States of America; University of Alabama at Birmingham, Birmingham, Alabama, United States of America","¶Membership of the PATH Study Investigators is provided in the Acknowledgments.","The authors have the following interests. Drs. Pratt and Lewis are inventors on a patent describing the SPR methodology described in this study. Dr. Pratt received travel support from GE Health Sciences to present preliminary SPR studies at the 2011 DiPia meeting in Boston, Massachusetts. This study was partly funded by Bayer HealthCare LLC. The authors thank Dr. Jason Schuman (GE Health Sciences) for technical advice and Bill Church (Green Mountain Antibodies, Burlington, Vermont) for donations of monoclonal antibodies. Drs. Lewis and Pratt are inventors on the following patent: International Patent Application No. PCT/US2012/61/553,660, Title: Antibody Response Phenotyping, Filed: October 31, 2012, Inventors: Kathleen Pratt, PhD; Kenneth Lewis, PhD. There are no further patents, products in development or marketed products to declare. This does not alter the authors′ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","05","Kenneth B Lewis","KBL",15,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
